Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells

Use of epidermal growth factor receptor (EGFR) inhibitors represented by gefitinib and erlotinib has become the standard of treatment for non-small-cell lung cancers (NSCLCs) with activating EGFR mutations. However, the majority of NSCLCs, which overexpress EGFR without such mutations, are resistant...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Suzuki, Shuhei, Okada, Masashi, Takeda, Hiroyuki, Kuramoto, Kenta, Sanomachi, Tomomi, Togashi, Keita, Seino, Shizuka, Yamamoto, Masahiro, Yoshioka, Takashi, Kitanaka, Chifumi
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2018
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6135698/
https://ncbi.nlm.nih.gov/pubmed/30220973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25994
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky